Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (Nasdaq: ZURA) is a clinical-stage, multi-asset immunology company whose news flow centers on the development of novel antibodies for autoimmune and inflammatory diseases. Company announcements frequently highlight progress in its clinical pipeline, financial updates, and key corporate developments.
A major focus of Zura Bio’s news is tibulizumab (ZB-106), its lead investigational dual-pathway antibody targeting IL-17A and BAFF. Press releases describe the advancement of two Phase 2 trials: TibuSHIELD, a global randomized, double-blind, placebo-controlled study in adults with moderate to severe hidradenitis suppurativa, and TibuSURE, a global Phase 2 trial in adults with systemic sclerosis. Updates often cover trial initiation, enrollment status, study design details, and anticipated timelines for topline data readouts.
Investors and observers will also find quarterly and annual financial results reported by Zura Bio, including information on research and development spending, general and administrative expenses, net loss, and cash and cash equivalents. These releases typically include the company’s expectations about its cash runway and its ability to fund planned operations and clinical programs.
Additional news items include corporate and leadership changes, such as executive appointments, board transitions, and the establishment of advisory structures, as well as participation in healthcare and investor conferences where Zura Bio presents corporate overviews. The company also issues updates related to equity inducement grants and other compensation matters.
This news page aggregates these disclosures so readers can follow Zura Bio’s clinical milestones, financial condition, and organizational updates in one place. For those tracking ZURA, the feed offers an organized view of how the company’s immunology programs and corporate strategy are evolving over time.
Zura Bio Limited (Nasdaq: ZURA) has appointed Michael D. Howell, Ph.D., as the new Chief Scientific Officer and Head of Translational Science. With over two decades of experience, Dr. Howell will spearhead the scientific strategy and translational research efforts at Zura Bio. Prior to this role, he was a scientific advisor during the company's formation in 2022. His extensive background includes leadership positions at DermTech, Incyte Corporation, and AstraZeneca. Zura Bio focuses on developing therapies for immune and inflammatory disorders and is advancing its pipeline, including Phase 2 programs like ZB-168 and torudokimab. CEO Someit Sidhu expressed confidence in Dr. Howell's expertise to drive the company’s science and clinical development forward.
Zura Bio Limited has successfully completed its business combination with JATT Acquisition Corp, announced on March 21, 2023. Prior to the merger, JATT's public shareholders redeemed 98.7% of their Class A ordinary shares, totaling 13,617,502 shares. Post-combination, Zura is advancing its immunology assets into Phase 2 development, focusing on ZB-168, an anti-IL7R α inhibitor targeting various inflammatory disorders, and torudokimab, a monoclonal antibody neutralizing IL33. Zura's growth is backed by promising Phase 1b results in Type 1 Diabetes, showcasing a favorable safety profile.
Zura Bio Limited, a clinical-stage biotechnology company focused on immunology, has completed its business combination with JATT Acquisition Corp. The merger, approved by JATT's shareholders on March 16, 2023, results in approximately $65 million in gross cash proceeds to support R&D initiatives and potential acquisitions. The combined entity will trade under the ticker symbol ZURA on Nasdaq starting March 21, 2023. The funds will be used for the clinical development of Zura's pipeline candidates, ZB-168 and torudokimab, with leadership from former Arena Pharmaceuticals executives. This milestone aims to enhance the company's immunology portfolio.